Neurélux

Transcranial photobiomodulation (tPBM) is the application of near-infrared light (typically 600–1100nm) non-invasively to the scalp to stimulate brain cells. Light penetrates the skull and is absorbed by mitochondria in neurons, increasing ATP production, reducing inflammation, and improving cerebral blood flow. It is a non-contact, non-invasive, and drug-free approach to brain wellness.

Preliminary clinical evidence suggests tPBM may support cognitive function in individuals with mild cognitive impairment (MCI) and early-stage dementia. Published studies report improvements in cognitive scores and brain metabolism markers. Neurélux's own 6-week fMRI pilot observed hippocampus volume increases of +1.835%. These are exploratory findings; larger RCTs are needed to confirm therapeutic efficacy. Neurélux is not a medical treatment device.

LED wavelength can shift as it heats up — this is a known characteristic of standard LED operation. This matters because cytochrome c oxidase, the main biological target in neurons, has narrow absorption peaks. Maintaining stable wavelength output throughout a session helps ensure reproducibility. HS FRAME™ is designed to keep wavelength and output stable from start to finish — supporting consistent session delivery.

An exploratory 6-week pilot study using Neurélux, presented at CES 2026, measured brain volume changes using fMRI before and after the intervention. Results showed hippocampus volume increased by +1.835% and cerebellum volume by +1.798% on average. These are preliminary, exploratory data from a small pilot cohort. They are not proof of medical efficacy. A follow-up confirmatory RCT is currently being designed to validate these initial signals under rigorous conditions.

Neurélux uses 810nm + 1064nm dual-band, which is a distinct wavelength combination not widely adopted by other home tPBM devices. It focuses on full transcranial coverage without intranasal application, and is powered by HS FRAME™ — a patented thermal management platform designed to minimize wavelength variation. Some competing brands have more published clinical studies. Neurélux has fMRI brain volume data from a 2026 pilot. Both are wellness devices, not FDA-cleared medical devices (as of 2026).

tPBM has a well-established safety profile across hundreds of published studies. Near-infrared light at the wavelengths and doses used in Neurélux is non-ionizing, non-thermal (no heat sensation), and non-invasive. No serious adverse events were reported in the Neurélux pilot study. Standard contraindications apply: avoid use over active malignancy, photosensitizing medications, or by pregnant women without physician guidance.